SELLAS Life Sciences (SLS) Return on Capital Employed (2012 - 2026)
SELLAS Life Sciences' (SLS) quarterly Return on Capital Employed came in at 35.03% in Q1 2026, up 10252.0% year-on-year from N/an in Q1 2025, and up 28.21% on a QoQ basis from 48.8% in Q4 2025.
SELLAS Life Sciences (SLS) Return on Capital Employed (2012 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 13 years of Return on Capital Employed data on file, last reported at 35.03% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 10252.0% year-over-year to 35.03% in Q1 2026; TTM through Mar 2026 was 35.03%, a 10252.0% increase from a year earlier, with the FY2025 full-year figure at 67.53%, up 88295.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 35.03%, up from 48.8% in the prior quarter.
- Over the last five years, Return on Capital Employed for SLS reached as high as 575.3% in Q4 2023 and fell as low as 4073.41% in Q1 2024.
- Historically, Return on Capital Employed has averaged 558.39% across 5 years, with a median of 300.31% in 2022.
- Across the five-year window, Return on Capital Employed slumped 368975 bps in 2024 and surged 393586 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 527.21% in 2022, then jumped by 209 bps to 575.3% in 2023, then slumped by 141 bps to 234.15% in 2024, then soared by 79 bps to 48.8% in 2025, then gained by 28 bps to 35.03% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 35.03% in Q1 2026, 48.8% in Q4 2025, and 74.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | -35.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.03% |
| Dec 31, 2025 | -48.80% |
| Sep 30, 2025 | -74.81% |
| Jun 30, 2025 | -98.38% |
| Mar 31, 2025 | -137.55% |
| Dec 31, 2024 | -234.15% |
| Sep 30, 2024 | -321.33% |
| Jun 30, 2024 | -450.16% |
| Mar 31, 2024 | -4,073.41% |
| Dec 31, 2023 | 575.30% |
| Sep 30, 2023 | -2,459.96% |
| Jun 30, 2023 | -354.55% |
| Mar 31, 2023 | -383.66% |
| Dec 31, 2022 | -527.21% |
| Sep 30, 2022 | -266.56% |
| Jun 30, 2022 | -300.31% |
| Mar 31, 2022 | -301.95% |
| Dec 31, 2021 | -93.23% |
| Sep 30, 2021 | -50.28% |
| Jun 30, 2021 | -40.54% |